1. American Cancer Society. Global Cancer Facts & Figures 2nd Edition. American Cancer Society, Atlanta. 2011. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-027766.pdf . Accessed 4 Aug, 2014.
2. Benson JR, Jatoi I. The global breast cancer burden. Future Oncol. 2012;8:697–702.
3. Swain S, Kim S, Cortes J, J. R, Semiglazov V, Campone M, et al. 350O_PR - Final overall survival (OS) analysis from the CLEOPATRA study of first-line (1 L) pertuzumab (Ptz), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC). European Society for Medical Oncology; 28.09.2014; Madrid, Spain 2014.
4. Tan SH, Wolff AC. Treatment of Metastatic Breast Cancer: Chemotherapy. In: Harris JR, Lippman ME, Morrow M, Osborne CK, editors. Diseases of the Breast, vol. 74. 4th ed. Philadelphia, PA: Lippincott-Raven Publishers; 2010. p. 877–919.
5. Montazeri A. Health-related quality of life in breast cancer patients: a bibliographic review of the literature from 1974 to 2007. J Exp Clin Cancer Res. 2008;27:32.